Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Operations (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Cash from Operations data on record, last reported at 34273000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 14.23% year-over-year to 34273000.0; the TTM value through Dec 2025 reached 711196000.0, up 760.42%, while the annual FY2025 figure was 711196000.0, 760.42% up from the prior year.
  • Cash from Operations reached 34273000.0 in Q4 2025 per PTCT's latest filing, up from 66301000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 870103000.0 in Q1 2025 and bottomed at 165963000.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 8144800.0, with a median of 53216000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: plummeted 430.28% in 2024, then soared 1129.64% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 68840000.0 in 2021, then crashed by 141.09% to 165963000.0 in 2022, then soared by 39.57% to 100288000.0 in 2023, then surged by 70.08% to 30004000.0 in 2024, then fell by 14.23% to 34273000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 34273000.0 in Q4 2025, 66301000.0 in Q3 2025, and 58333000.0 in Q2 2025.